Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel–Lindau (VHL) disease-associated haemangioblastoma
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714 · cited 2×
“13 The sponsor concluded this event was unrelated to the drug.”
HIF activation identifies early lesions in VHL kidneys
Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliffe, P. J., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00071-5 · Cited by 483
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01324-7 · Cited by 305
Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor
Scheuermann, T. H., Tomchick, D. R., Machius, M., Guo, Y., Bruick, R. K., & Gardner, K. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808092106 · Cited by 301
Biswas, S., Troy, H., Leek, R., Chung, Y.-L., Li, J.-L., Raval, R. R., Turley, H., Gatter, K., Pezzella, F., Griffiths, J. R., et al. (2010) · Journal of Oncology · doi:10.1155/2010/757908 · Cited by 89
Research works printed but not linked: 18
- Latif, 1993, Identification of the von Hippel-Lindau disease tumor suppressor gene, Science, 260, 1317, 10.1126/science.8493574 · DOI · Paper page
- Maher, 1990, Clinical features and natural history of von Hippel-Lindau disease, Q J Med, 77, 1151, 10.1093/qjmed/77.2.1151 · DOI · Paper page
- Binderup, 2017, Survival and causes of death in patients with von Hippel-Lindau disease, J Med Genet, 54, 11, 10.1136/jmedgenet-2016-104058 · DOI · Paper page
- Gossage, 2015, VHL, the story of a tumour suppressor gene, Nat Rev Cancer, 15, 55, 10.1038/nrc3844 · DOI · Paper page
- Zhang, 2022, Clinical characteristics and risk factors for survival in affected offspring of von Hippel-Lindau disease patients, J Med Genet, 59, 951, 10.1136/jmedgenet-2021-108216 · doi:10.1136/jmedgenet-2021-108216
- Wang, 2018, Risk factors for survival in patients with von Hippel-Lindau disease, J Med Genet, 55, 322, 10.1136/jmedgenet-2017-104995 · doi:10.1136/jmedgenet-2017-104995
- Kaelin, 2022, Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer, J Clin Invest, 132, 10.1172/JCI162480 · DOI · Paper page
- Rogers, 2013, Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor, J Med Chem, 56, 1739, 10.1021/jm301847z · DOI · Paper page
- Iliopoulos, 2024, Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study, Lancet Oncol, 25, 1325, 10.1016/S1470-2045(24)00389-9 · DOI · Paper page
- Dhawan, 2022, First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma, CNS Oncol, 11, 10.2217/cns-2022-0008 · DOI
- Choueiri, 2022, LITESPARK-022: a phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC), J Clin Oncol, 40
- Choueiri, 2025, Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study, Lancet Oncol, 26, 64, 10.1016/S1470-2045(24)00649-1 · DOI
- Choueiri, 2024, Belzutifan versus everolimus for advanced renal-cell carcinoma, N Engl J Med, 391, 710, 10.1056/NEJMoa2313906 · DOI · Paper page
- Trinh, 2023, FDA approval summary: belzutifan for VHL disease tumors—letter, Clin Cancer Res, 29, 10.1158/1078-0432.CCR-22-2968 · DOI
- Gläsker, 2005, Risk of hemorrhage in hemangioblastomas of the central nervous system, Neurosurgery, 57, 10.1227/01.NEU.0000163250.71951.18 · doi:10.1227/01.neu.0000163250.71951.18
- Ene, 2015, Spontaneous hemorrhage from central nervous system hemangioblastomas, World Neurosurg, 83, 1180.e13, 10.1016/j.wneu.2015.02.009 · doi:10.1016/j.wneu.2015.02.009
- Saeed, 2023, Fatal intracranial hemorrhage with belzutifan in von Hippel-Lindau disease-associated hemangioblastoma: a case report, JCO Precis Oncol, 7
- Jonasch, 2018, Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial, Lancet Oncol, 19, 1351, 10.1016/S1470-2045(18)30487-X · DOI · Paper page
Metadata
- Authors
- Shepherd, S. T. C., Kelly-Morland, C., Drage, S., Brady, A. F., Macwana, R., Pickering, L., Larkin, J., Hill, P., & Turajlic, S.
- Venue
- ESMO Open
- Publisher
- Elsevier BV
- Published
- 2025-05
- Volume
- 10
- Issue
- 5
- Pages
- 105109
- ISSN
- 2059-7029
- Cited by
- 6
- References
- 6
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- VHL Alliance (PRJ_20450)
- National Institutes of Health (U01 CA247439)
- Melanoma Research Alliance (686061)
- National Institute for Health and Care Research
- Wellcome Trust
- NIHR Maudsley Biomedical Research Centre
- Medical Research Council
- The Francis Crick Institute
- Institute of Cancer Research (A29911, FC10988, A109)
- U.S. Department of Defense (W81XWH-22-1-0652)
- Rosetrees Trust (A2204)
- Royal Marsden Cancer Charity
- Cancer Research UK (FC010110)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.